Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Monopar Therapeutics changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 13 | 13 | 0 |
| Shares | 204.2K | 204.5K | +253 (+0.1%) |
| Value | $657.2K | $519.8K | −$137.5K (−20.9%) |
New holders (2)
Institutions that held Monopar Therapeutics at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Glassman Wealth Services | 1 | $0 | 0.00% |
| IFP Advisors, Inc | 500 | – | – |
Sold out (2)
Institutions that held Monopar Therapeutics at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Captrust Financial Advisors | 170 | $1.00K |
| Bank of America Corp | 7 | $0 |